Delcath Systems (DCTH)
NASDAQ:DCTH
Want to see DCTH full AI Analyst Report?
DCTH Stock Chart & Stats
$10.86
-$0.29(-2.36%)
At close: 4:00 PM EST
$10.86
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.12 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)307.27K
Market Cap
$396.31M
Enterprise Value$355.90M
Total Cash (Recent Filing)$89.30M
Total Debt (Recent Filing)$907.00K
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Aug 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding34,521,650
10 Day Avg. Volume277,602
30 Day Avg. Volume307,271
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda1.10K
Forecast
1Y Price Target
$25.25Price Target Upside132.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$102.69M
Bulls Say, Bears Say
Bulls Say
Clinical Data PublicationPublication of the CHOPIN clinical dataset in a major oncology journal could raise physician awareness and drive increased adoption of Hepzato, particularly when used with checkpoint inhibitors.
Clinical VersatilityThe CHOPIN protocol’s compatibility with systemic therapies and its support for treating disease outside the liver expands the pool of eligible patients and gives physicians greater flexibility in scheduling treatment.
Commercial ExpansionActivation of multiple new treatment sites combined with an expanded regional sales force should broaden the referral network, increase patient access, and support meaningful sales growth as new sites begin treating patients.
Bears Say
Competitive ApprovalRegulatory approval of a competing drug for metastatic uveal melanoma could divert referrals and reduce near-term uptake of Hepzato by increasing market competition.
Financial Guidance And ProfitabilityRevenue guidance below market expectations, together with the lag between site activations and patient starts and rising R&D and sales expenses, may delay realization of expected sales and pressure near-term profitability.
Reimbursement RiskNet pricing is sensitive to hospital participation in the 340B program, which can significantly reduce reimbursement for eligible patients and compress margins.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.12 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $396.31M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Aug 10, 2026 which is in 92 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.067.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.09.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,521,650 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went down -0.178%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.25 (132.50% Upside)
$25.25 (132.50% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 69.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.62%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
42.97%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$25.25
▲(132.50% Upside)
Technical Analysis
Ownership Overview
21.79% Insiders
7.33% Mutual Funds
1.61% Other Institutional Investors
60.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---